Simultaneous Determination of Contezolid and Its Metabolite M2 in Human Plasma and Cerebrospinal Fluid by Ultra-High-Performance Liquid Chromatography – Tandem Mass Spectrometry (UHPLC-MS/MS)-Reference-Cited by-同舟云学术

Simultaneous Determination of Contezolid and Its Metabolite M2 in Human Plasma and Cerebrospinal Fluid by Ultra-High-Performance Liquid Chromatography – Tandem Mass Spectrometry (UHPLC-MS/MS)

Published:2023-11-08 Issue: Volume: Page:1-18
ISSN:0003-2719
Container-title:Analytical Letters
language:en
Short-container-title:Analytical Letters

Author:

Xie Chufei¹²³,Zhang Dongjie²,Wu Lei⁴,Shi Guangzhi⁴,Wang Hailin⁵,Cao Yanmei⁵,Bian Xiaohe⁵,Wang Wenjing⁶,Zhao Lichun¹³,Mei Shenghui²

Affiliation:

1. College of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guiyang, China

2. Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

3. College of Pharmaceutical Sciences, Guangxi University of Traditional Chinese Medicine, Nanning, China

4. Department of Intensive Care Unit, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

5. Clinical Department, Shanghai MicuRx Pharmaceutical, Shanghai, China

6. Beijing Institute of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing, China

Funder

National Key R&D Program of China

Open Projects at Clinical Institutes and Departments of Capital Medical University

Qi-Huang Chief Scientist Project of National Administration of Traditional Chinese Medicine

Publisher

Informa UK Limited

Subject

Electrochemistry,Biochemistry (medical),Clinical Biochemistry,Spectroscopy,Biochemistry,Analytical Chemistry

Link

https://www.tandfonline.com/doi/pdf/10.1080/00032719.2023.2276213

Reference20 articles.

1. Anon. 2007. C50-A: CLSI Standards & Guidelines: Shop for CLSI Standards. Clinical & Laboratory Standards Institute .

2. Anon. 2011. EMEA: Committee for medicinal products for human use guideline on bioanalytical method validation.

3. Anon. 2013. Bioanalytical method validation guidance for industry | FDA.

4. In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe

5. Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects